Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Developing subject-specific biomarkers of preclinical Alzheimer's disease through evaluation of age-related pathophysiological compromises on large-scale functional coupling dynamics

FY 2014-15

Summary
As the population ages, the prevalence of Alzheimer's disease (AD) is expected to increase dramatically. By 2030, there will be more than 1.4 million affected Canadians that will pose a major challenge to our healthcare system and society. From a clinical perspective, both improved treatment and early diagnosis of AD is required to avert this impending healthcare crisis. Changes occur in the brain in AD patients decades before clinical signs of dementia are observed (the preclinical phase) and by the time a diagnosis of AD is established by current methods, substantial damage has already occurred in the brain, limiting the effectiveness of neuroprotective treatments. The goal of the present proposal is to develop an individualized, non-invasive biomarker of preclinical AD that can be differentiated from normal ageing processes. The primary hypothesis centers on the notion that brain areas must communicate with one another in dynamic configurations over time for normal cognition to occur. AD pathology disrupts this intricate interplay, particularly between regions involved in memory processes, compromising the ability to exchange information and impairing cognitive function. Advanced imaging techniques will be used to capture this disordered brain activity across a range of afflicted adults and compared with the current standard in diagnostic and clinical assessments to determine its prognostic value. By elucidating the link between the pathological cascade of AD and time-varying brain activity and developing a reliable, non-invasive biomarker there will be greater opportunity for therapeutic intervention that could drive improved disease modification and prevention trials.
Program
Banting Postdoctoral Fellowship Program
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
315602
Name
Hutchison R Matthew
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Developing subject-specific biomarkers of preclinical Alzheimer's disease through evaluation of age-related pathophysiological compromises on large-scale functional coupling dynamics
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Aging; Alzheimer'S Disease; Amyloid-Beta Deposition; Brain Dynamics; Dynamic Coupling; Functional Imaging; Medial Temporal Lobe; Memory; Structural Imaging; Tau Deposition
Abstract
As the population ages, the prevalence of Alzheimer's disease (AD) is expected to increase dramatically. By 2030, there will be more than 1.4 million affected Canadians that will pose a major challenge to our healthcare system and society. From a clinical perspective, both improved treatment and early diagnosis of AD is required to avert this impending healthcare crisis. Changes occur in the brain in AD patients decades before clinical signs of dementia are observed (the preclinical phase) and by the time a diagnosis of AD is established by current methods, substantial damage has already occurred in the brain, limiting the effectiveness of neuroprotective treatments. The goal of the present proposal is to develop an individualized, non-invasive biomarker of preclinical AD that can be differentiated from normal ageing processes. The primary hypothesis centers on the notion that brain areas must communicate with one another in dynamic configurations over time for normal cognition to occur. AD pathology disrupts this intricate interplay, particularly between regions involved in memory processes, compromising the ability to exchange information and impairing cognitive function. Advanced imaging techniques will be used to capture this disordered brain activity across a range of afflicted adults and compared with the current standard in diagnostic and clinical assessments to determine its prognostic value. By elucidating the link between the pathological cascade of AD and time-varying brain activity and developing a reliable, non-invasive biomarker there will be greater opportunity for therapeutic intervention that could drive improved disease modification and prevention trials.
Competitiondate
201409
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Hutchison, R Matthew
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~